• We offer tailored partnerships to support and transform drug discovery.

    Every collaboration is a bespoke arrangement, meticulously designed to discover new compounds and targets in patient relevant disease models.

  • MIMETAS offers flexible fee-for-service solutions for therapy prioritization, optimization, and de-risking of compounds.

    As an extension of your team, MIMETAS provides the expertise and resources needed for effective research and development.

  • Our OrganoReady program is made for you when you need optimized assays for investigational toxicology.

    We guarantee OrganoReady performance according to specifications, in a fast and convenient sales transaction with a clear fee structure.

  • Giving you some food for thought. Read our blogs to learn more about 3D tissue culture, research backgrounds, developments, and its future outlook.
  • Get inspired by research done by our scientists, partners, and customers around the globe.

  • Learn about our mission, vision, the history of the company, and find out what we mean with MIMETAS-do.
open menu icon close menu icon

App Note: A 3D human blood-brain barrier model in a high throughput platform for disease modeling and drug development

There is an unmet need for human-relevant blood-brain barrier models to better enable discovery of novel therapeutics to treat CNS disorders. Most BBB models are either limited in their complexity, failing to mimic key aspects of the BBB, or lack human translatability.

In this app note, we describe a 3D primary human brain microvascular endothelial cell (HBMEC) BBB model which displays physiologically relevant junction and transporter expression profiles, low small molecule permeability, all while being compatible with robust high-throughput readouts such as high-content imaging and sensitive on-chip TEER measurements. The BBB on-a-chip model is ideal for fundamental studies of BBB function in health and disease and for investigation of potential restorative therapies to fight neurological disorders. Due to the platform’s high throughput and compatibility with automation, the model is also optimized to facilitate compound screening workflows.

Benefits of the model:

  • 40 or 64 robust human BBBs-on-chips in a perfused microfluidic platform
  • Tight barrier function as evidenced by retention of a small molecule dye
  • Expression of relevant BBB transporters & response to barrier-disrupting compound


Download the app note here


May we use cookies?
Hi there! Thanks for visiting our website. We use cookies to keep track of our website statistics to optimize the user experience. We also use cookies for marketing purposes. You can set your preferences by selecting the options below. Terms of Use & Privacy Policy
Accept all
Accept selected
Decline all